Compare EPAC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | BEAM |
|---|---|---|
| Founded | 1910 | 2017 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | EPAC | BEAM |
|---|---|---|
| Price | $40.35 | $27.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $50.50 | $48.09 |
| AVG Volume (30 Days) | 568.7K | ★ 1.6M |
| Earning Date | 12-17-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $615,911,000.00 | $55,701,000.00 |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $5.97 | $26.52 |
| P/E Ratio | $24.28 | ★ N/A |
| Revenue Growth | ★ 3.91 | N/A |
| 52 Week Low | $35.01 | $13.53 |
| 52 Week High | $47.47 | $35.25 |
| Indicator | EPAC | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 60.09 |
| Support Level | $35.01 | $26.17 |
| Resistance Level | $40.43 | $28.29 |
| Average True Range (ATR) | 1.35 | 1.35 |
| MACD | 0.25 | 0.07 |
| Stochastic Oscillator | 77.23 | 78.58 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.